981.0500 9.90 (1.02%)
NSE Apr 06, 2026 15:52 PM
Volume: 217.4K
 

981.05
1.02%
Ashika Research
operational flexibility. It has a diversified product portfolio with 300+ products including nutraceuticals, Rx soft gelatin capsules, sachets and oral solids in wide ranging therapies. Strides has 8...
Geojit BNP Paribas upgraded Strides Pharma Science Ltd. to Buy with a price target of 1119.0 on 27 Mar, 2026.
More from Strides Pharma Science Ltd.
Recommended